Alerta

NOVEL ALPK1 INHIBITORS

Resumen de: WO2026012438A1

The disclosure is directed to novel ALPK1 inhibitors having the Formula (I), or a pharmaceutical acceptable salt, a stereoisomer, a tautomer, an atropisomer, a stable isotopic variant, a prodrug, or a crystal form thereof. The disclosure is also directed to pharmaceutical composition comprising the novel ALPK1 inhibitors, and use thereof in treating inflammation related diseases, such as ROSAH syndrome, inflammatory bowel disease (IBD), NASH, gout, diabetes, chronic kidney disease, pancreatitis, Kawasaki disease, inflammatory skin diseases and neurodegenerative diseases including the Alzheimer's disease.

METHODS AND SYSTEMS FOR TREATMENT OF NEURODEGENERATIVE DISEASE AND USES THEREOF

Resumen de: WO2026015576A1

The present disclosure provides methods of treatment of neurodegenerative disease, such as a motor neuron disease, in subjects in need thereof. A therapeutically effective dose of a suitable mast cell stabilizer may be administered to suitable subjects, wherein the suitability of a subject is determined by the rate of progression of the disease over time or by the severity of the disease. A therapeutically effective dose of a suitable mast cell stabilizer may be administered to suitable subjects, wherein the suitability of a subject is determined by subject genotype and/or family genotypes or medical history. In certain embodiments, the therapy may comprise a cromolyn homolog salt, and suitable subjects are persons with amyotrophic lateral sclerosis (ALS). In certain embodiments, the subjects are patients with slow progressing ALS and/or the subjects have mild to moderate ALS. In certain embodiments, the subjects are persons with sporadic ALS or persons without familial ALS.

METHODS FOR THE TREATMENT OF SYMPTOMS OF NEUROLOGICAL AND MENTAL HEALTH DISORDERS

Resumen de: US20260016491A1

A therapeutic composition for the treatment of the symptoms of neurological and mental health disorders, such as Alzheimer's disease, bipolar disorder, obsessive compulsive disorder, and oppositional defiant disorder, and the method for preparing the therapeutic agents is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using fecal chymotrypsin level as an indicator of the presence of neurological and mental health disorders, such as Alzheimer's disease, bipolar disorder, obsessive compulsive disorder, and oppositional defiant disorder, or the likelihood of an individual to develop these disorders is disclosed.

COMPOUND INCLUDING 2,4-DIAMINOPYRIDINE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER

Resumen de: US20260015340A1

The present disclosure relates to an isobenzofuran-1(3H)-one derivative, which is a kinase inhibitor, and a use thereof and, more specifically, to an isobenzofuran-1(3H)-one derivative having HPK1 inhibitory activity and MLK3 inhibitory activity and a pharmaceutical composition containing same for preventing or treating cancer, virus infectious diseases, Parkinson's disease, non-alcoholic steatohepatitis, or tuberculosis. In addition, the compound can be advantageously used as a composition for prevention or treatment of cancer as it is administered in combination with an anticancer agent or a cell therapy product.

Levodopa and Carbidopa Intestinal Gel and Methods of Use

Resumen de: US20260014108A1

The present disclosure provides (a) a pharmaceutical composition comprising a levodopa active agent and a carbidopa active agent and (b) methods of treating Parkinson's disease and associated conditions comprising administering the pharmaceutical composition to a subject with Parkinson's disease.

MMP-14 OR TIMP POTENCY ASSAY FOR MESENCHYMAL STEM CELLS

Resumen de: US20260014205A1

Compositions and methods are disclosed herein for the treatment of neurocognitive disorders or central nervous system (CNS) disorders such as Alzheimer's disease (AD) and congenital heart diseases such as hypoplastic left heart syndrome (HLHS) with allogeneic mesenchymal stem cells (MSCs). The methods of treatment involve an administration of a composition of allogeneic mesenchymal stem cells to a subject in need thereof, wherein the effectiveness of the treatment methods can be determined through the measurement of specific biomarkers.

FENCHOL AS A STIMULATOR OF FREE FATTY ACID RECEPTOR AND OTHER USES THEREOF

Resumen de: US20260014098A1

Described are methods of treating neurodegenerative disease by administering a therapeutically effective amount of fenchol to a patient in need thereof. Additionally, described are methods of activating FFAR2 signaling in a patient by administering a therapeutically effective amount of fenchol to a patient in need thereof. Methods of treating gastrointestinal disorders in a patient being treated for cancer and methods of improving cognition in a patient being treated for cancer are also described. Further, the present disclosure provides for a pharmaceutical composition including fenchol and an Alzheimer's disease drug. Additionally, a nasal spray including fenchol, a buccal tablet including fenchol, and a dietary supplement including fenchol are described.

ACTIVATORS OF THE TMEM175 ION CHANNEL

Resumen de: WO2026015890A1

The present invention is directed to activators of TMEM175 Ion Channel, which are compounds of Formulae: (AAA), (AA), (A), (I), (II), (III), (IV), (V), (VI), (B), (B-I), and (B-II). The activators described herein can be useful in the treatment of diseases or disorders associated with disfunction of TMEM175 Ion Channel, such as Neurological Disorders, Parkinson's Disease, Alzheimer's disease, dementia with Lewy bodies (DEB), multisystem atrophy (MSA), progressive supranuclear palsy (PSP). In particular, the invention is concerned with compounds and pharmaceutical compositions activating TMEM175 Ion Channel in a cell, methods of treating diseases or disorders associated with disfunction of TMEM175 Ion Channel, and methods of synthesizing these compounds.

COMBINATION OF METFORMIN AND GLIBENCLAMIDE IN THE TREATMENT OF PARKINSON'S DISEASE

Resumen de: AU2024232317A1

The present invention provides a pharmaceutical composition comprising metformin and glibenclamide for use in the treatment of Parkinson's disease. The invention also comprises a combined administration of metformin and glibenclamide. In a preferred embodiment, the administration is made through oral route.

DUAL INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE

Resumen de: CN120813572A

Compounds (I) are provided, wherein R1 and R2 are H or (C1-C3)-alkyl; x is a linear methylene chain of formula-CH2 n-, n = 0, 1 or 2, or is a divalent group of a branched saturated (C2-C4)-alkylene chain; and A is a C-group from a non-aromatic polycyclic 6 to 15 membered carbocyclic system, or a C-group from a polycyclic 6 to 15 membered heterocyclic system having one or two of O, S or N; wherein the C-group is unsubstituted or substituted. Compound (I) is both an inhibitor of soluble epoxide hydrolase and an inhibitor of glutaminyl cyclase. In addition, compound (I) reduces the level of pro-inflammatory cytokines in LPS-stimulated BV2 cells, shows low cytotoxicity and has good BBB permeability. Therefore, they are useful as multi-target compounds for the prevention or treatment of Alzheimer's disease.

TREATMENT OF PARKINSON'S DISEASE IN A PATIENT USING A GLUCOCEREBROSIDASE ACTIVATOR

Nº publicación: EP4676488A1 14/01/2026

Solicitante:

BIAL R&D INVEST S A [PT]
Bial-R&D Investments, S.A

Resumen de: MX2025010647A

Methods for preventing, limiting or delaying clinical motor progression in a subject with Parkinson's disease with low GCase activity, such as a PD patient with a pathogenic variant in the glucocerebrosidase 1 (GBA1) gene (GBA-PD) is provided, said methods comprising administering a therapeutically effective amount of 5,7-dimethyl-N-((1R,4R)-4- (pentyloxy)cyclohexyl)pyrazolol1,5-apyrimidine-3-carboxamide (Compound A), or a pharmaceutically acceptable salt thereof, to said subject.